Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection.

BACKGROUND Infection with Trichomonas vaginalis during pregnancy has been associated with preterm delivery. It is uncertain whether treatment of asymptomatic trichomoniasis in pregnant women reduces the occurrence of preterm delivery. METHODS We screened pregnant women for trichomoniasis by culture of vaginal secretions. We randomly assigned 617 women with asymptomatic trichomoniasis who were 16 to 23 weeks pregnant to receive two 2-g doses of metronidazole (320 women) or placebo (297 women) 48 hours apart. We treated women again with the same two-dose regimen at 24 to 29 weeks of gestation. The primary outcome was delivery before 37 weeks of gestation. RESULTS Between randomization and follow-up, trichomoniasis resolved in 249 of 269 women for whom follow-up cultures were available in the metronidazole group (92.6 percent) and 92 of 260 women with follow-up cultures in the placebo group (35.4 percent). Data on the time and characteristics of delivery were available for 315 women in the metronidazole group and 289 women in the placebo group. Delivery occurred before 37 weeks of gestation in 60 women in the metronidazole group (19.0 percent) and 31 women in the placebo group (10.7 percent) (relative risk, 1.8; 95 percent confidence interval, 1.2 to 2.7; P=0.004). The difference was attributable primarily to an increase in preterm delivery resulting from spontaneous preterm labor (10.2 percent vs. 3.5 percent; relative risk, 3.0; 95 percent confidence interval, 1.5 to 5.9). CONCLUSIONS Treatment of pregnant women with asymptomatic trichomoniasis does not prevent preterm delivery. Routine screening and treatment of asymptomatic pregnant women for this condition cannot be recommended.

[1]  Ichael,et al.  Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. , 2000, The New England journal of medicine.

[2]  G. Ma,et al.  A study on the potential role of Trichomonas vaginalis in transmission of Herpes simplex virus type II. , 1999 .

[3]  H. Bruinse,et al.  Prophylactic administration of clindamycin 2 % vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo‐controlled double‐blind trial , 1999, British journal of obstetrics and gynaecology.

[4]  D. Levy,et al.  Surveillance for waterborne-disease outbreaks--United States, 1995-1996. , 1998, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[5]  P. McDonald,et al.  Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised, placebo controlled trial , 1997, British journal of obstetrics and gynaecology.

[6]  W. Mccormack,et al.  Trichomoniasis in pregnancy. , 1997, Sexually transmitted diseases.

[7]  M. Krohn,et al.  Trichomonas vaginalis Associated With Low Birth Weight and Preterm Delivery , 1997, Sexually transmitted diseases.

[8]  M. Krohn,et al.  Bacterial colonization of the vagina during pregnancy in four ethnic groups. , 1996, American journal of obstetrics and gynecology.

[9]  J. Hauth,et al.  Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis , 1995, The New England journal of medicine.

[10]  S. Hillier,et al.  Intravaginal clindamycin treatment for bacterial vaginosis: effects on preterm delivery and low birth weight. , 1995, American journal of obstetrics and gynecology.

[11]  John A. Albritton,et al.  Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. , 1994, American journal of obstetrics and gynecology.

[12]  J. French,et al.  Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream. , 1994, American journal of obstetrics and gynecology.

[13]  R. P. Heine,et al.  Trichomonas vaginalis: Diagnosis and Clinical Characteristics in Pregnancy , 1994, Infectious diseases in obstetrics and gynecology.

[14]  J. Mcgregor,et al.  Trichomonas Vaginalis: A Reemerging Pathogen , 1993, Clinical obstetrics and gynecology.

[15]  M A Krohn,et al.  Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation , 1991, Journal of clinical microbiology.

[16]  L Ryan,et al.  Survival analysis in natural history studies of disease. , 1989, Statistics in medicine.

[17]  L. J. Wei,et al.  Properties of the urn randomization in clinical trials. , 1988, Controlled clinical trials.

[18]  J. Feldman,et al.  Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy. , 1984, American journal of obstetrics and gynecology.

[19]  P. Hardy,et al.  PREVALENCE OF SIX SEXUALLY TRANSMITTED DISEASE AGENTS AMONG PREGNANT INNER-CITY ADOLESCENTS AND PREGNANCY OUTCOME , 1984, The Lancet.

[20]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[21]  Isabel Morgan Metronidazole Treatment in Pregnancy , 1978, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[22]  A. Grice Vaginal Infection Causing Spontaneous Rupture of the Membranes and Premature Delivery , 1974 .